| Brand Name | Ravenbhel Healthcare |
|---|---|
| Industry | Healthcare Products / Pharmaceuticals |
| Business Category | Contract Development & Manufacturing (CDMO) |
| Founded Year | 1987 |
| Franchise Started Year | Operational franchise program details not explicitly specified, B2B partnerships active |
| Total Franchise Outlets | 100–200 |
| Estimated Investment | INR 10,000 – 50,000 |
| Franchise Fee | Typically includes onboarding or partnership initiation fees |
| Royalty Fee | Structured according to contract agreements with B2B partners |
| Space Requirement | 100–200 sq.ft for office/distribution functions |
| Staff Requirement | Small administrative and sales team |
| Expected Payback Period | 1–2 years |
Ravenbhel Healthcare operates in the pharmaceutical and healthcare products sector, providing contract development, manufacturing, and regulatory support services. The brand serves pharmaceutical companies seeking outsourcing solutions for drug formulation, production, and packaging.
This franchise falls under the healthcare product CDMO category, targeting B2B partners rather than end consumers. It focuses on delivering compliant, scalable, and cost-effective manufacturing solutions to both domestic and international pharmaceutical companies.
Franchise operations involve facilitating B2B partnerships, managing client relationships, and coordinating production projects. Customers (pharmaceutical companies) submit contract manufacturing requests, which progress through R&D, formulation, production, and quality assurance. Daily operations include project management, regulatory documentation support, and client communications. Revenue is generated through service fees, production contracts, and long-term partnerships.
| Contract Manufacturing | Generic and specialty pharmaceutical formulations |
|---|---|
| Formulation Development | Novel or value-added dosage forms |
| R&D Services | Bioequivalence, stability studies, and regulatory support |
| Packaging Services | End-to-end product packaging solutions |
| Compliance & Quality Assurance | Regulatory documentation and QA support for global markets |
Franchise partners act as business development and liaison offices for B2B operations. Partners manage client acquisition, project coordination, and local sales efforts. Outlets operate under Ravenbhel Healthcare’s standardized procedures for project initiation, manufacturing coordination, and regulatory compliance. Franchisor support ensures consistent service delivery, client satisfaction, and operational efficiency.
| Estimated Investment | INR 10,000 – 50,000 |
|---|---|
| Franchise Fee | Typically structured as an onboarding or B2B partnership fee |
| Setup Costs | Office infrastructure, administrative tools, and business development resources |
| Royalty Payments | Managed through contract-based revenue-sharing arrangements |
The investment reflects office-based operations rather than capital-intensive manufacturing facilities.
| Space Requirement | 100–200 sq.ft for administrative and client coordination purposes |
|---|---|
| Preferred Locations | Urban areas accessible to pharmaceutical companies, hospitals, and distributors |
| Equipment Needs | Office setup including computers, communication systems, and record-keeping infrastructure |
| Staffing Considerations | Small team for administration, business development, and client coordination |
Franchisor support includes:
| Operational Training | Guidance on client management, project coordination, and regulatory compliance |
|---|---|
| Launch Assistance | Office setup and onboarding processes |
| Marketing Support | Networking with pharmaceutical companies and brand promotion |
| Supply Chain Systems | Access to manufacturing units, R&D, and packaging facilities |
| Ongoing Guidance | Project oversight, regulatory updates, and operational troubleshooting |
Revenue is generated through contract manufacturing fees, formulation development services, and long-term B2B partnership agreements. Pricing models are project-based, with demand driven by domestic and international pharmaceutical clients seeking compliant CDMO solutions. Operational cost factors include office overhead, staff salaries, and client service activities. Payback is typically achieved within 1–2 years.
| Founded Year | 1987 |
|---|---|
| Franchise Network | 100–200 B2B partners/outlets |
| Geographic Presence | India with expanding global partnerships |
| Expansion Goals | Strengthen partnerships in regulated international markets, including EU and US; acquire EU-GMP and US FDA certifications; expand R&D capabilities |
Ravenbhel Healthcare leverages two WHO-GMP certified manufacturing facilities and a robust R&D framework to support franchise partners in scalable pharmaceutical operations.
Operational distinctions:
Ravenbhel Healthcare offers a low-capital B2B partnership model connecting franchisees to regulated pharmaceutical manufacturing, with structured operational support and international market reach.
Investment ranges from INR 10,000 – 50,000, covering office setup, administrative tools, and onboarding. Fees are typically structured to facilitate B2B partnerships rather than direct manufacturing investments.
Franchisees manage client relations and coordinate contract manufacturing projects, working with central R&D and manufacturing units. Operations focus on B2B support, order management, and compliance monitoring.
Operations can be conducted in 100–200 sq.ft of office space suitable for administrative work and client coordination.
Franchise partners can expect payback within 1–2 years depending on contract volume, client acquisition, and operational efficiency.
Interested partners submit applications outlining experience, financial readiness, and potential client network. Franchisor provides onboarding, operational guidance, and marketing support for B2B client engagement. ## 14. Similar Franchise Opportunities
Disclaimer: All scores, rankings, and estimates on ForeFind are independently produced editorial assessments using publicly available data and validated brand-submitted information. They are not verified facts, financial advice, or investment recommendations. Full Disclaimer.